CSF Markers: Goodbye, Research Use Only; Hello, Clinical
When it comes to CSF Aβ and tau measurements, pharma companies developing Alzheimer’s disease treatments and diagnosing clinicians share similar goals...
586 RESULTS
Sort By:
When it comes to CSF Aβ and tau measurements, pharma companies developing Alzheimer’s disease treatments and diagnosing clinicians share similar goals...
At the Alzheimer’s Association International Conference, two companies presented their progress toward oligomer-measuring assays...
Results of a nine-year longitudinal study indicate that women with the highest amounts of certain types of ceramide in their blood are more likely to develop Alzheimer’s disease...
Data from the DIAN paint a sobering picture, showing that a cascade of pathophysiological changes begins decades before a person is likely to develop familial AD...
A healthy brain switches between its different functional networks like a well-oiled machine, but as dementia takes over, communication becomes disorganized...
Scientists from academia, industry, and funding organizations met to discuss precompetitive steps in the preparation for clinical trials for frontotemporal degeneration...
Women run a higher risk of getting Alzheimer’s disease than do men, yet surprisingly little is known about how gender interacts with the disease or affects the brain...
Testing a widely used cerebrospinal fluid Aβ42 immunoassay, scientists proposed modifications that they believe improve its precision and accuracy...
The Dominantly Inherited Alzheimer Network Pharma Consortium met in Washington, D.C., to exchange the latest information on DIAN’s preparation for therapeutic trials...
Identifying injuries that might lead to chronic traumatic encephalopathy or other neurodegenerative pathologies, and then treating those injuries, are two major challenges...
Injury to the brain, even what might be considered mild, can have devastating consequences on brain physiology...
Increasingly, upcoming trials for Alzheimer's therapeutics will target prevention—seeing whether drugs can stave off the disease before it takes hold...
The total tau to amyloid-β42 ratio from cerebrospinal fluid reliably distinguishes Alzheimer’s disease from frontotemporal degeneration...
Researchers have been measuring Aβ for decades, trying to nail down its behavior in Alzheimer's patients or those nearing the disease...
The stuff touted to confer anti-aging properties on foods from blueberries to dark chocolate does no good for people with Alzheimer’s disease—and might even make them worse...